A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys

American Journal of Medical Genetics, Part A

Volumn 146, Issue 7, 2008, Pages 803-812

  Torrioli, M Giulia ^a   Vernacotola, Silvia ^a   Peruzzi, Laura ^a   Tabolacci, Elisabetta ^a   Mila, Montserrat ^b   Militerni, Roberto ^c   Musumeci, Sebastiano ^d   Ramos, Feliciano J ^e   Frontera, Marìa ^f   Sorge, Giovanni ^g   Marzullo, Elisabetta ^g   Romeo, Giusi ^g   Vallee, Louis ^h   Veneselli, Edvige ⁱ   Cocchi, Elena ⁱ   Garbarino, Eleonora ⁱ   Moscato, Umberto ^a   Chiurazzi, Pietro ^a   D'Iddio, Stefania ^j   Calvani, Menotti ^j   Neri, Giovanni ^a   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d OASI RESEARCH INSTITUTE IRCCS   (Italy)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f UNIVERSITY OF ZARAGOZA   (Spain)

^g UNIVERSITY OF CATANIA   (Italy)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ G GASLINI INSTITUTE   (Italy)

^j Sigma Tau SpA   (Italy)

more..

Author keywords

Attention deficit hyperactivity disorder; Conners' Global Index; Fragile X syndrome; L acetylcarnitine; Vineland Adaptive Behavior Scale

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; LEVACECARNINE; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITION; CONNERS GLOBAL INDEX PARENTS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DISEASE ASSOCIATION; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FRAGILE X SYNDROME; GENE MUTATION; GENETIC ANALYSIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SOCIAL ASPECT; SOCIALIZATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VINELAND ADAPTIVE BEHAVIOR SCALE; VOMITING;

EID: 41849117708     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32268     Document Type: Article

References (42)

1. Aman MG, Kern RA, McGhee DE, Arnold LE. 1993. Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. J Am Acad Child Adolesc Psychiatry 32:851-859.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association.
3. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. 1995. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 95:744-752.
4. Bremer J. 1983. Carnitine: Metabolism and function. Physiol Rev 63:1420-1480.
5. Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G. 1998. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 7:109-113.
6. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. 2007. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 37:738-747.
7. Conners CK. 1990. Conners' rating scales revised-technical manual. New York: Multi-Health Systems, Inc.
8. Daniel WW. 2005. Biostatistics. A foundation for analysis in the health sciences. Georgia: John Wiley & Sons.
9. Dell'Anna E, Iuvone L, Calzolari S, Geloso MC. 1997. Effect of acetyl-L-carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia. Neurosci Lett 223:201-205.
10. Dolezal V, Tucek S. 1981. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J Neurochem 36:1323-1330.
11. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. 2004. Relative carnitine deficiency in autism. J Autism Dev Disord 34:615-623.
12. Fryns JP, Jacobs J, Kleczlowska A, Van den Berghe H. 1984. The psychological profile of the Fragile X Syndrome. Clin Genet 25:131-134.
13. Gibson GE, Shimada M. 1980. Studies on the metabolic pathway of the acetyl group for acetylcholine synthesis. Biochem Pharmacol 29:167-174.
14. Gorini A, D'Angelo A, Villa RF. 1998. Action of L- acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex. Neurochem Res 23:1485-1491.
15. Gorini A, D'Angelo A, Villa RF. 1999. Energy metabolism of synaptosomal subpopulations from different neuronal systems of rat hippocampus: effect of L-acetylcarnitine administration in vivo. Neurochem Res 24:617-624.
16. Guideri F, Acampa M, Hayek Y, Zappella M. 2005. Effects of acetyl-L-carnitine on cardiac dysautonomia in Rett syndrome: Prevention of sudden death? Pediatr Cardiol 26:574-577.
17. Hagerman RJ. 2002. Medical follow-up and pharmacotherapy. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: Diagnosis, treatment and research. Baltimore: The Johns Hopkins University Press. p 287-338.
18. Hagerman RJ, Hagerman PJ, editors. 2002. Fragile X syndrome: Diagnosis, treatment and research. 3rd edition. Baltimore: The Johns Hopkins University Press.
19. Hagerman RJ, Murphy MA, Wittenberger MD. 1988. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 30:377-392.
20. Handen BL, Breaux AM, Gosling A, Ploof DL, Feldman H. 1990. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder. Pediatrics 86:922-930.
21. Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S. 1991. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 30:241-245.
22. Handen BL, Janosky J, McAuliffe S. 1997. Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD. J Abnorm Child Psychol 25:287-295.
23. Imperato A, Ramacci MT, Angelucci L. 1989. Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci Lett 107:251-255.
24. Klein-Schwartz W. 2002. Abuse and toxicity of methylphenidate. Curr Opin Pecliatr 14:219-223.
25. Kuratsune H, Watanabe Y, Yamaguti K, Jacobsson G, Takahashi M, Machii T, Onoe H, Onoe K, Matsumura K, Valind S, Kitani T, Langstrom B. 1997. High uptake of (2-11C)acetyl-L-carnitine into the brain: A PET study. Biochem Biophys Res Commun 231:488-493.
26. Maccari F, Arseni A, Chiodi P, Ramacci MT, Angelucci L. 1990. Levels of carnitines in brain and other tissues of rats of different ages: Effect of acetylcarnitine administration. Exp Gerontol 25:127-134.
27. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
28. Pascale E, Battiloro E, Cimino Reale G, Pietrobono R, Pomponi MG, Chiurazzi P, Nicolai R, Calvani M, Neri G, D'Ambrosio E, 2003. Modulation of methylation in the FMR1 promoter region after long term treatment with L-carnitine and acetyl-L-carnitine. J Med Genet 40:e76.
29. Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti P, Calvani M. 2001. Carnitine: An osmolyte that plays a metabolic role. J Cell Biochem 80:1-10.
30. Pomponi MG, Neri G. 1994. Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am J Med Genet 51:447-450.
31. Pueschel SM. 2006. The effect of acetyl-L-carnitine administration on persons with Down syndrome. Res Dev Disabil 27:599-604.
32. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, Bagni C, Ammassari-Teule M. 2005. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci USA 102:11557-11562.
33. Snow K, Doud L, Hagerman R, Hull C, Hirst MC, Davies KE, Thibodeau SL. 1992. Analysis of mutations at the fragile X locus using the DNA probe Ox1.9. Am J Med Genet 43:244-254.
34. Sonnewald U, Westergaard N, Hassel B, Muller TB, Unsgard G, Fonnum F, Hertz L, Schousboe A, Petersen SB. 1993. NMR spectroscopic studies of 13C acetate and 13C glucose metabolism in neocortical astrocytes: Evidence for mitochondrial heterogeneity. Dev Neurosci 15:351-358.
35. Sparrow SS, Balla DA, Cicchetti DV. 1984. Vineland adaptive behavior scales. Minnesota: American Guidance Service.
36. Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G. 2005. Differential epigenetic modifications in the FMRl gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 13:641-648.
37. Tassone F, Hagerman RJ, Taylor AK, Hagerman PJ. 2001. A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. J Med Genet 38:453-456.
38. Torrioli MG, Vernacotola S, Mariotti P, Bianchi E, Calvani M, De Gaetano A, Chiurazzi P, Neri G. 1999. Double blind, placebo-controlled crossover study of L-acetylcarnitine for the treatment of Fragile X syndrome. Am J Med Genet 87:366-368.
39. Toth E, Harsing LG Jr, Sershen H, Ramacci MT, Lajtha A. 1993. Effect of acetyl-L-carnitine on extracellular amino acid levels in vivo in rat brain regions. Neurochem Res 18:573-578.
40. Van Oudheusden LJ, Scholte HR. 2002. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 67:33-38.
41. Wechsler D. 1974. Wechsler intelligence scale for children revised. New York: The Psychological Corporation.
42. Willemsen R, Anar B, De Diego Otero Y, de Vries BB, Hilhorst-Hofstee Y, Smits A, van Looveren E, Willems PJ, Galjaard H, Oostra BA. 1999. Non invasive test for fragile X syndrome, using hair root analysis. Am J Hum Genet 65:98-103.